Breaking News, Collaborations & Alliances

NeoStem, Kite Pharma Enter Process Development Pact

To provide development and manufacture for eACT clinical program

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy (PCT), have entered a services agreement with Kite Pharma to provide cell therapy process development and manufacturing services for Kite’s lead Autologous T Cell Therapy (eACT) clinical development program.   Kite Pharma’s eACT is designed to restore the immune system’s ability to recognize and eradicate tumors. Kite’s lead eACT clinical development program, anti-CD19 CAR T cells, aims to treat aggressive lymphoma. PCT ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters